Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

FOXC1 induces cisplatin resistance through enhancer activation [RNA-seq_FOXC1_KO]

ABSTRACT: FOXC1 induces cisplatin resistance through enhancer activation [RNA-seq_FOXC1_KO]

PROVIDER: PRJNA716298 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR14034441_1.fastq.gz	Fastqsanger.gz
	SRR14034441_2.fastq.gz	Fastqsanger.gz
	SRR14034442_1.fastq.gz	Fastqsanger.gz
	SRR14034442_2.fastq.gz	Fastqsanger.gz
	SRR14034443_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

FOXC1 induces cisplatin resistance through enhancer activation

Project description:FOXC1 induces cisplatin resistance through enhancer activation

| PRJNA716292 | ENA

FOXC1 induces cisplatin resistance through enhancer activation [ChIP-seq]

Project description:FOXC1 induces cisplatin resistance through enhancer activation [ChIP-seq]

| PRJNA716294 | ENA

FOXC1 induces cisplatin resistance through enhancer activation [RNA-Seq_SPNSP]

Project description:FOXC1 induces cisplatin resistance through enhancer activation [RNA-Seq_SPNSP]

| PRJNA716297 | ENA

FOXC1 induces cisplatin resistance through enhancer activation [RNA-Seq_SPNSP]

Project description:We previously reported that an aggressive subpopulation of highly tumorigenic, drug-resistant bladder cancer cells can arise from the bulk tumor cells without mutational events and that this phenotypic plasticity is driven at least in part by epigenetic mechanisms. In the current work, we analyzed the chromatin accessibility of enhancers to identify transcription factors that contribute to this transition to a drug-resistant state. Comparing the drug resistant side population (SP) cells and the less drug resistant non-side population (NSP) cells in bladder cancer cells, we identified differential accessible enhancers and differentially expressed genes. Transcription factor motif analysis showed that FOX family motif was enriched in accessible enhancers near SP-overexpressed genes. Among FOX family transcription factors, FOXC1 was the only overexpressed transcription factor, and it was also the most significantly overexpressed gene in SP cells. FOXC1 ChIP-seq confirmed that FOXC1 binding sites are more accessible in SP cells and showed a significantly more FOXC1 binding near the overexpressed genes in SP cells. When the FOXC1 is knocked out, bladder cancer cells exhibit decreased cisplatin resistance and less percentage of SP cells. This change in cisplatin resistance is partially related to the FOXC1-driven expression of ABCB1 gene. In summary, our observations suggest that differential expression and enhancer binding of FOXC1 promotes the previously observed, mutation-independent shift towards cisplatin resistance in bladder cancer.

2022-04-01 | GSE169335 | GEO

FOXC1 induces cisplatin resistance through enhancer activation [RNA-seq_FOXC1_KO]

2022-04-01 | GSE169334 | GEO

FOXC1 induces cisplatin resistance through enhancer activation [ChIP-seq]

2022-04-01 | GSE169333 | GEO

FOXC1 induces cisplatin resistance through enhancer activation

Project description:This SuperSeries is composed of the SubSeries listed below.

2022-04-01 | GSE169336 | GEO

Enhancer recruitment of transcription repressors RUNX1 and TLE3 by mis-expressed FOXC1 blocks differentiation in acute myeloid leukemia

Project description:Despite absent expression in normal hematopoiesis, the Forkhead factor FOXC1, a critical mesenchymal differentiation regulator, is highly expressed in ~30% of HOXAhigh AML to confer blocked monocyte/macrophage differentiation. Through integrated proteomics and bioinformatics, we discovered that FOXC1 and RUNX1 interact through Forkhead and Runt domains respectively and cooccupy primed and active enhancers distributed close to differentiation genes. FOXC1 stabilises association of RUNX1, HDAC1 and Groucho repressor TLE3 to limit enhancer activity: FOXC1 knockdown induced loss of repressor proteins, gain of CEBPA binding, enhancer acetylation and upregulation of nearby genes, including KLF2. Furthermore, it triggered genome-wide redistribution of RUNX1, TLE3 and HDAC1 from enhancers to promoters leading to repression of self-renewal genes including MYC and MYB. Our studies highlight RUNX1 and CEBPA transcription factor swapping as a feature of leukemia cell differentiation, and reveal that FOXC1 prevents this by stabilising enhancer binding of a RUNX1/HDAC1/TLE3 transcription repressor complex, to oncogenic effect.

2021-08-08 | PXD027740 | Pride

Foxc1 establishes enhancer accessibility for craniofacial cartilage differentiation

Project description:Foxc1 establishes enhancer accessibility for craniofacial cartilage differentiation

| PRJNA661770 | ENA

Foxc1 establishes enhancer accessibility for craniofacial cartilage differentiation

Project description:The specification of cartilage requires Sox9, a transcription factor with broad roles for organogenesis outside the skeletal system. How Sox9 gains selective access to cartilage-specific cis-regulatory regions during skeletal development had remained unclear. By analyzing chromatin accessibility during the differentiation of neural crest cells into chondrocytes of the zebrafish head, we find that cartilage-associated chromatin accessibility is dynamically established. Cartilage-associated regions that become accessible after neural crest migration are co-enriched for Sox9 and Fox transcription factor binding motifs. In zebrafish lacking Foxc1 paralogs, we find a global decrease in chromatin accessibility in chondrocytes, consistent with a later loss of dorsal facial cartilages. Zebrafish transgenesis assays confirm that many of these Foxc1-dependent elements function as enhancers with region- and stage-specific activity in facial cartilages. We propose that Foxc1-dependent chromatin accessibility helps directs the versatile Sox9 protein to a chondrogenic program in the face.

2020-12-31 | GSE157575 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data